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A B S T R A C T
Purpose: Nearly half of all patients with seizure onset in the ﬁrst year of life suffer from West syndrome
(WS). The prognosis of epilepsy and psychosocial outcomes in children with WS are variable. This study
was performed to examine the factors inﬂuencing the outcome of this patient population.
Methods: A total of 109 patients with WS followed up regularly for at least 3 years were included in the
study. Relevant clinical, laboratory, and imaging data were collected.
Results: The male/female ratio was 65/44 (59.6%/40.4%). The mean age at onset of infantile spasm (IS)
was 6  6 (1–36) months. With regard to neuro-developmental and social conditions during the ﬁnal
evaluation, 29.4% of the patients were socially dependent on caregivers, 61.8% needed assistance, and 8.8%
were normal. Among the patients, 5.9% were free of epilepsy and antiepileptic drugs (AED) for at least 2 years,
49.0% had no seizures with AEDs, and 45.1% had uncontrollable seizures. Parameters with signiﬁcant
negative effects on the long-term outcomes included symptomatic etiology, presence of developmental
retardation before the onset of IS, persistence of active epilepsy, and male gender.
Conclusion: In this study, 37 (33.9%) patients had severe consequences as a result of WS. The majority of
the rest could cope with daily life with varying degrees of assistance. Eight percent of the patients had a
normal development. These results draw attention to the two-thirds of patients with WS who have the
chance of an acceptable quality of life (QoL) with early diagnosis and therapeutic measures.
 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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West syndrome (WS) is the most frequently occurring infantile
epileptic encephalopathy with a yearly incidence of 2–4.5/10,000
and a prevalence of 1.5–2/10,000 at 10 years of age or older [1].
Approximately 50% of patients with seizure onset before 12
months of age, excluding the neonatal period, suffer from WS
characterized by infantile spasm (IS), psychomotor arrest or
retardation, and hypsarrhythmia on electroencephalograms (EEG)
[2–4]. Epileptic spasms most often show a temporal relationship
with hypsarrhythmia, which is the typical interictal EEG activity in
WS. Both spasms and focal seizures in WS are frequently* Corresponding author at: Bakirkoy Research and Training Hospital for
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and in such cases, either polypharmacy and/or steroids are applied
to suppress epileptic phenomena, although this has only been
partially successful. There have been relatively few reports
regarding the long-term prognosis of epilepsy and its impact
on the daily life of patients with WS [4,5]. Both the prognosis
of epilepsy and cognitive outcomes of WS are related to the
etiological characteristics of the syndrome, as cryptogenic WS
(cWS) has a more favorable outcome than symptomatic WS (sWS)
[6–9]. Normal or subnormal cognitive development has been
reported in approximately 25% of adult patients with previous
WS [5]. The prognostic consequences of WS have been causally
related to various additional parameters, such as premorbid
developmental status, age at onset of WS, time and type of
management [10–13]. The present study was performed to
examine the long-term consequences of epilepsy and the psycho-
social impacts of WS in the patient population under long-term
follow-up in our center.served.
Table 1
Demographic and clinical features of the patients.
n = 109a/%
Follow-up duration, years 8 (3–16)
Gender 65M/44F
Mean age at the last visit, years 9.5  4 (3–19)




Patients with pre-spasm partial seizures 35/31.2















Patients with parental consanguinity 30/27.5
Patients having relatives with epilepsy and/or
febrile seizures
17/15.6
Patients with inborn metabolic diseases 3/2.7
Cranial MRI results
Normal 29/26.6
Diffuse cortical and/or subcortical involvement 57/52.3
Unilateral cortical and/or subcortical involvement 16/14.7
Others 2/1.8
IS: infantile spasm. CNS: central nervous system.
a Seven deceased patients were included.
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Data belonging to a total of 109 patients with WS recruited
since 1991 and followed up for at least 3 years in our WS outpatient
clinic were included in the study. Last controls were completed in
2013. Patients with lack of recent information were called back and
reevaluated to collect the missing data. Diagnosis of WS was
conﬁrmed by interviews, clinical observations, and analyses
of video-EEGs. Patients were examined at least once a year until
6–7 years of age; regular follow-ups were once in 1–3 years later, if
epilepsy was stabilized by then. Almost all patients underwent
cranial magnetic resonance imaging (cMRI) and laboratory tests,
including biochemical screening and tests for inborn metabolic
diseases. Etiologically, patients were grouped as sWS, cWS, or
idiopathic WS (iWS) according to the proposed ILAE classiﬁcation
scheme [14]. According to the neuro-developmental and social
conditions during the ﬁnal evaluation, the patients were divided
into three categories: Group A, the ‘‘normal living group’’, patients
with normal or subnormal motor and intellectual outcomes with
favorable social status; Group B, the ‘‘assisted living group’’,
ambulatory patients receiving special academic and/or physical
support to cope with social needs; Group C, the ‘‘dependent living
group’’, patients with severe motor and/or mental impairment
with solely supervised living. Those groups were determined based
on our neurological evaluations, interviews with the parents and
on consultation reports of child-psychiatrists. Patients were
grouped according to the status of epilepsy as follows: Group in
remission, no epilepsy or treatment for at least 2 years; Group
under control, epilepsy under control for a minimum of 2 years
with AED treatment; Group active, persistent seizures despite AED
treatment. The cMRI ﬁndings were classiﬁed as normal, diffuse
cortical and/or subcortical involvement, or unilateral cortical and/
or subcortical involvement.
The following parameters were included in the statistical
evaluation: the age of onset of spasms and partial seizures, gender,
family history of seizures, presence of parental consanguinity,
presence of developmental delay or neurological deﬁcit prior to the
onset of spasms, etiology, characteristics of cognitive and motor
involvement during the active phase of WS and later follow-ups,
response of epilepsy to treatment, and clinic status of epilepsy
during follow-ups.
Continuous variables are expressed as means  SD, and
categorical variables are presented as frequencies and percentages.
The chi-square test was used to compare the differences in categorical
variables among the groups. SPSS 17.0 statistical software (SPSS,
Chicago, IL, USA) was used for the statistical analysis. In all analyses,
P < 0.05 was taken to indicate statistical signiﬁcance.
This study was approved by Ethics Committee of Cerrahpas¸ a
Medical Faculty, University of Istanbul, Turkey.
3. Results
A total of 109 patients with WS were included in this study. The
study population consisted of 65 male (59.6%) and 44 (40.4%)
female with a mean follow-up duration of 8 years (3–16 years)
(Table 1).
The number of patients as distributed to the groups with
different neuro-developmental and social conditions was as
follows: Group A, n = 9 (8.3%), Group B, n = 63 (57.8%), and Group
C, n = 30 (27.5%). Seven deceased subjects were not included in
these groups. Six patients (5.5%) free of epilepsy and AEDs
were classiﬁed as the Group in remission. Epileptic seizures
were under control by AEDs in 50 patients (45.9%, Group under
control) and persisted despite AEDs in 46 (42.2%, Group active)
(Table 2).Valproic acid (p53) (30–50 mg/kg/day), vigabatrin (p26)
(50–100 mg/kg/day), and ACTH (p21) (0.5–1 mg/day) are the
ﬁrst-line drugs for WS (Table 3).
The number of females (n = 7) versus males (n = 2) in Group A
was compared with the number of females (n = 34) versus males
(n = 59) in groups B and C combined, and a statistically signiﬁcant
difference was found in favor of females. Females showed
better long-term performance in neuro-developmental and social
outcomes (P = 0.04).
Patients were divided into three groups according to the age at
onset of IS: 0–3, 4–9, and 10 months. There were no correlations
among prognostic variables, such as neuro-developmental and
social performances and severity of epilepsy, among the types of IS,
the age at onset of IS, and the presence or absence of neuro-
developmental deﬁcits before the onset of IS. Interestingly, the
presence of partial seizures showed an inverse relationship with
the age at onset of IS, as partial seizures were present before IS in
81.3%, 24.5%, and 21.2% of patients with spasm onset at 10, 4–9,
and 0–3 months, respectively (P < 0.001) (Table 4).
Seventy of 74 (94.6%) patients with pre-IS neuro-developmen-
tal involvement and 23 of 28 (82.1%) patients with normal pre-IS
development were present in Group C, and this was signiﬁcant
(P = 0.03).
The presence of pre-spasm focal seizures and the type of spasm
did not show a signiﬁcant relationship with clinical outcome with
regard to the neuro-developmental and social performances of the
patients. Of 93 patients in Groups B and C, 85 (91.3%) showed sWS.
Eighty-ﬁve of 92 patients (91.3%) with sWS were in Groups B
and C, and only 7 (7.6%) were in Group A. One of nine patients in the
cWS group and a single patient in the iWS groups were in Group A.
Symptomatic etiology was signiﬁcantly related to poor prognosis
(P = 0.01).
The presence of active epilepsy was signiﬁcantly related to the
neuro-developmental and social performances of the patients. All
Table 2
Characteristics of epilepsy and neuro-developmental/social outcomes.
Neuro-developmental and social outcomes Group A (n = 9) Group B (n = 63) Group C (n = 30) P
Follow-up period, months 128  47 (48–180) 100  46 (36–192) 90  43 (36–180) 0.98
Gender (F/M) 7/2 22/41 12/18 0.04
Age at onset of IS 6.7  5 (1–17) 6.4  5 (1–30) 5.4  6 (1–36) 0.73
Neuro-developmental deﬁcit pre-IS
Absent 5 19 4 0.03
Present 4 44 26
Focal seizures pre-IS
Present 8 41 20 0.35
Absent 1 22 10
Type of IS
Symmetric 9 58 13 0.19
Asymmetric – 5 –
Etiology
Idiopathic 1 – –
Cryptogenic 1 7 1 0.01
Symptomatic 7 56 29
Parental consanguinity
Absent 8 49 19 0.19
Present 1 14 11
Epilepsy/FS in relatives
Absent 9 55 24 0.28
Present – 8 6
Response to AEDs
Group in remission 2 3 1 0.02
Group under control 7 30 13
Group active – 30a 16a
Group A: normal living group; Group B: assisted living group; Group C: dependent living group.
Group in remission: No AED, no seizures; Group under control: AED + no seizures; Group active: AED + seizures + IS: Infantile spasm; AED: Antiepileptic drug; FS: Febrile
seizure.
If p value is < 0.05, this is signiﬁcant result.
a Patients with sWS.
Table 4
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AED treatment. The proportions of seizure-free patients were
33/63 (52.4%) in Group B and 14/30 (46.6%) in Group C (P = 0.02).
All 46 patients with active epilepsy were in the sWS group.
4. Discussion
Although WS is a major type of infantile epilepsy, there is a
paucity of data regarding the prognostic consequences of this
syndrome. Special efforts may be needed to closely follow-up
patients after they grow out of childhood, or to be informed if death
occurs in another hospital setting or at home. In many countries,
there are insufﬁcient institutions for chronically disabled patients
and a lack of interdisciplinary and interinstitutional communica-
tion, which may exacerbate this issue. In the present study, we
examined the long-term outcomes of our patients with WS and
searched for early variables that may have an impact on their
quality of life (QoL) later in life. Various studies have indicated that
age at onset of epileptic spasms is related to poor prognosis in WS.
In a group of patients with cWS, the onset of spasms during the ﬁrst
month of life was reported to be a factor indicating poor outcome,
while that after age 4 months indicated a better outcome [8,15].
The age at onset of spasms in the present study did not seem
to inﬂuence either the neuro-developmental outcome or the
prognosis of epilepsy later in life. However, the presence of early
focal seizures was shown to be positively related to late onset
(i.e., 10 months) of spasms. This may be because epilepticTable 3
Treatment of WS.
N:109 %
Valproic acid 53 48.6
Vigabatrin 26 23.9
ACTH 21 19.3
Phenobarbital 9 8.2seizures with marked motor manifestations are alarming for the
parents, and spasms may go unnoticed or misdiagnosed during
the early stages. Although this may be valid in some cases, the
majority of the focal seizures prior to spasms had subtle clinical
manifestations in these patients. Another question is whether focal
seizures produce some competitive inhibitory effect on the
development of epileptic spasms for a limited time during the
early postnatal stage. Epileptic spasms can be related to focal
lesions in the brain as well as to diffuse anatomical or functional
disturbances [16]. However, the EEG correlates of these spasms,
despite variable morphological characteristics, are almost always a
generalized paroxysmal discharge, even in patients with hemi-
hypsarrhythmia [17]. A delayed effect of generalized epilepsy
on the onset of experimental focal seizures in some studies on
adult rats with genetically determined deﬁciencies was reported
previously [18,19]. Here, the situation was the opposite, suggesting
that the focal ﬁring can produce a delayed effect on the
maturational processes including myelination, which are neces-
sary for generalization of epileptic discharges.
In our study, boys had a slightly less (P = 0.04) favorable course
with regard to neuro-developmental and social performances
compared with girls. A study on rat pups showed that sex
hormones can affect epileptogenesis in the developing brain, and
that the immature brain of males is more vulnerable to the insult
than the female brain [20]. This may provide some support for theRelationship between the age at onset of IS and the presence/absence of pre-IS focal
seizures.
Age at onset of IS Pre-IS focal seizures P
Present (n = 69/%) Absent (n = 33/%)
0–3 months (n = 33) 26/78.8 7/21.2
4–9 months (n = 53) 40/75.5 13/24.5
10 months (n = 16) 3/18.8 13/81.3 <0.001
IS: infantile spasm.
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study.
Neuro-developmental involvement prior to IS, a feature that
mostly indicates the pre- or perinatal etiology, was a poor
prognostic variable in the present study. Riikonen [4,5] reported
that patients of WS with a favorable outcome had normal neuro-
development before the onset of the spasms. Nearly all previous
studies on this variable reported similar results [3,7,10,21–26]. The
presence of parental consanguinity and epilepsy in near relatives
showed no signiﬁcant effect on prognosis in this study. The results
of a study on a heterogeneous epileptic population including WS
patients in Saudi Arabia where the consanguinity rate was 53% did
not indicate this parameter as a major factor affecting the genetics
of the study group [27]. A study on a heterogeneous group of
children with progressive encephalopathy with autosomal reces-
sive (AR) involvement, however, revealed an 11-fold increased risk
in consanguineous Pakistani patients compared with a non-
consanguineous Norwegian cohort [28]. Evidence suggests that
although many genetic disorders may lead to WS in infants, AR
disorders do not play a major role among the diverse etiologies.
The presence of epilepsy within family members also had no effect
on the outcome of our patients.
Epilepsy was stabilized, with or without AED treatment, in
more than half (54.9%) of our patients at the latest visit. The
remaining patients had intractable seizures. All patients with
ongoing epilepsy at the latest visit had sWS. At the end of 5 years,
the rate of epilepsy remission was 28% in a group of WS patients
within a cohort with symptomatic epilepsies in a previous study,
[29] whereas it was considerably higher (52%) in the present study.
Some aspects regarding the details of the clinical and EEG
characteristics of epilepsy and the therapeutic and neuro-
developmental outcome measures of our patient population will
be discussed in later reports.
In this study, during the follow-up period, 37 of 109 (33.9%)
patients (including those deceased) had developed severe con-
sequences from WS. The majority of the remaining patients were
able to cope with daily life with varying degrees of assistance. Eight
percent of the patients had a normal QoL. The limitations of our
study are that the data is retrospective and it does not include
treatment of patients.
5. Conclusion
The results of the present study suggest that in patients with
WS symptomatic etiology, the presence of focal seizures, neuro-
developmental involvement before the onset of spasms, and poor
response to AEDs are indicators of poor prognosis with future
disability. Thus, early etiological diagnosis and treatment are
required to minimize the effects later in life in these patients.
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